FDA/Industry Least Burdensome Collaboration To Follow Release Of Guidance
This article was originally published in The Gray Sheet
FDA will meet with industry to discuss the agency's implementation of least burdensome requirements for premarket submissions, following the pending release of a draft guidance document.
You may also be interested in...
FDA's use of postmarket studies as a condition of approval for two transmyocardial revascularization devices is a fitting example of how to apply the "least burdensome" principles to the device review process as mandated by the 1997 FDA Modernization Act, suggests a coalition of medical device organizations.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.